The antimicrobial resistance profile of Streptococcus pneumoniae

R R Reinert1

  • 1International Scientific & Clinical Affairs, Vaccines, Wyeth Pharmaceuticals, La Défense, Paris, France. ReinerR@wyeth.com

Insights

Antibacterial resistance in Streptococcus pneumoniae is rising globally, with 40% of strains showing multidrug resistance. Understanding resistance mechanisms and vaccine impacts is crucial for combating this trend.

Area of Science:

  • Microbiology
  • Epidemiology
  • Molecular Biology

Background:

  • Increasing global antibacterial resistance in Streptococcus pneumoniae, particularly to beta-lactams and macrolides.
  • Understanding resistance determinants and evolution is key to addressing this public health challenge.
  • The Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin (PROTEKT) study provides insights into resistance patterns.

Purpose of the Study:

  • To investigate the molecular mechanisms and epidemiological trends of antibiotic resistance in Streptococcus pneumoniae.
  • To analyze the impact of antibiotic use and vaccination programs on pneumococcal resistance and disease prevalence.

Main Methods:

  • Analysis of data from the PROTEKT study on pneumococcal isolates.
  • Identification of molecular determinants of resistance, including alterations in penicillin-binding proteins (PBPs) and specific resistance genes (erm(B), mef(A), mef(E)).
  • Evaluation of epidemiological data related to antibiotic resistance and vaccine impact, including serotype replacement.

Main Results:

  • Approximately 40% of pneumococci exhibit multidrug-resistant phenotypes, with significant international variation.
  • Beta-lactam resistance is associated with alterations in six specific penicillin-binding proteins.
  • Macrolide resistance is mediated by the erm(B) gene or the mef(A)/mef(E) genes, often found in serotype 14 strains.
  • Pneumococcal conjugate vaccine (PCV7) introduction led to decreased disease from targeted serotypes but increased prevalence of non-PCV7 serotypes (e.g., 19A).

Conclusions:

  • Molecular mechanisms like PBP alterations and specific resistance genes drive antibiotic resistance in Streptococcus pneumoniae.
  • Vaccination strategies influence pneumococcal epidemiology, potentially leading to serotype replacement and the emergence of resistant strains.
  • Continued surveillance and research are essential to manage evolving antibacterial resistance and vaccine-induced epidemiological shifts.

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...